Stocksigma LogoStocksigma Logo

Sakar Healthcare Expands Global Oncology Footprint and Secures Key Regulatory Approvals

Sakar Healthcare is accelerating its oncology exports across the EU, UK, APAC, Canada, and LatAm, securing 22 Marketing Authorisations out of 190

Sakar Healthcare Expands Global Oncology Footprint and Secures Key Regulatory Approvals

Sakar Healthcare Ltd 路 Others (Uncategorized) 路 14 Oct 2026, 7:31 pm

Sakar Healthcare Expands Global Oncology Footprint and Secures Key Regulatory Approvals Sakar Healthcare is accelerating its oncology exports across the EU, UK, APAC, Canada, and LatAm, securing 22 Marketing Authorisations out of 190 submissions globally. The company achieved 11 site-variation approvals with major MNCs and received two CEP approvals out of seven applications for its 21 in-house APIs to support vertical integration. Commercial supplies have commenced from its EU GMP-approved oncology FDF facility. Additionally, management clarified that proposed domestic MRP caps on oncology drugs will not impact operations, as business is export-skewed and trade margin caps leave manufacturer realizations unaffected.

Original exchange filing (PDF)

More announcements from Sakar Healthcare Ltd

All Sakar Healthcare Ltd announcements